No Association of Multiple Sclerosis with
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Hémoglobine C : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer l'hémoglobine C ?
Un test sanguin spécifique, comme l'électrophorèse de l'hémoglobine, permet de diagnostiquer.
#2
Quels tests sont utilisés pour l'hémoglobine C ?
Les tests incluent l'électrophorèse et le dosage de l'hémoglobine C dans le sang.
#3
L'hémoglobine C est-elle héréditaire ?
Oui, l'hémoglobine C est une condition génétique transmise par les parents.
#4
Quels symptômes indiquent un test pour l'hémoglobine C ?
Des symptômes comme l'anémie ou des douleurs abdominales peuvent justifier un test.
#5
Peut-on détecter l'hémoglobine C à la naissance ?
Oui, le dépistage néonatal peut inclure des tests pour l'hémoglobine C.
Symptômes 5
#1
Quels sont les symptômes de l'hémoglobine C ?
Les symptômes incluent fatigue, jaunisse, et douleurs osseuses ou abdominales.
#2
L'hémoglobine C cause-t-elle de l'anémie ?
Oui, l'hémoglobine C peut entraîner une anémie due à la destruction des globules rouges.
#3
Y a-t-il des complications liées à l'hémoglobine C ?
Des complications peuvent inclure des crises douloureuses et des infections fréquentes.
#4
Les symptômes varient-ils selon l'âge ?
Oui, les symptômes peuvent être plus prononcés chez les enfants et les jeunes adultes.
#5
L'hémoglobine C provoque-t-elle des douleurs ?
Oui, des douleurs peuvent survenir en raison de la vaso-occlusion des vaisseaux sanguins.
Prévention 5
#1
Peut-on prévenir l'hémoglobine C ?
Étant génétique, l'hémoglobine C ne peut pas être prévenue, mais des conseils génétiques aident.
#2
Le dépistage est-il recommandé ?
Oui, le dépistage est recommandé pour les personnes à risque, notamment les porteurs.
#3
Comment éviter les complications ?
Une bonne hydratation et des soins médicaux réguliers aident à éviter les complications.
#4
Les conseils génétiques sont-ils utiles ?
Oui, les conseils génétiques aident les familles à comprendre les risques de transmission.
#5
Y a-t-il des vaccinations recommandées ?
Oui, des vaccinations contre certaines infections sont recommandées pour les patients.
Traitements 5
#1
Comment traite-t-on l'hémoglobine C ?
Le traitement peut inclure des transfusions sanguines et des médicaments pour l'anémie.
#2
Les transfusions sont-elles nécessaires ?
Des transfusions peuvent être nécessaires en cas d'anémie sévère ou de complications.
#3
Y a-t-il des médicaments spécifiques pour l'hémoglobine C ?
Des médicaments comme l'hydroxyurée peuvent être prescrits pour réduire les crises.
#4
La thérapie génique est-elle une option ?
La thérapie génique est en recherche, mais pas encore une option standard pour l'hémoglobine C.
#5
Comment gérer les crises douloureuses ?
Des analgésiques et une hydratation adéquate aident à gérer les crises douloureuses.
Complications 5
#1
Quelles sont les complications possibles ?
Les complications incluent des infections, des crises douloureuses et des problèmes hépatiques.
#2
L'hémoglobine C augmente-t-elle le risque d'infections ?
Oui, les patients ont un risque accru d'infections en raison de l'anémie et de la splénomégalie.
#3
Y a-t-il un risque de crise vaso-occlusive ?
Oui, les crises vaso-occlusives peuvent survenir, provoquant des douleurs intenses.
#4
Les problèmes hépatiques sont-ils fréquents ?
Des problèmes hépatiques peuvent survenir, surtout en cas de transfusions fréquentes.
#5
Comment surveiller les complications ?
Des examens réguliers et des bilans sanguins aident à surveiller les complications.
Facteurs de risque 5
#1
Quels sont les facteurs de risque de l'hémoglobine C ?
Les facteurs incluent des antécédents familiaux et l'origine ethnique, notamment africaine.
#2
L'origine ethnique influence-t-elle le risque ?
Oui, les personnes d'origine africaine ou méditerranéenne sont plus à risque.
#3
Les antécédents familiaux sont-ils importants ?
Oui, avoir des membres de la famille atteints augmente le risque de développer l'hémoglobine C.
#4
Le mode de vie affecte-t-il le risque ?
Un mode de vie sain peut réduire les complications, mais ne prévient pas la condition.
#5
Les femmes enceintes doivent-elles être testées ?
Oui, le dépistage est recommandé pour les femmes enceintes à risque d'hémoglobine C.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/04/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Mei Zhang
2 publications dans cette catégorie
Affiliations :
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Publications dans "Hémoglobine C" :
-
[Hemoglobin C Variant Affecting Glycated Hemoglobin Test Results: A Rare Case Report].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
-
[Effects of Hemoglobin Variants on Glycosylated Hemoglobin Testing].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Benjamin Fröhlich
2 publications dans cette catégorie
Affiliations :
- 1Physical Chemistry of Biosystems, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany.
Publications dans "Hémoglobine C" :
-
Hemoglobin S and C affect biomechanical membrane properties of
Communications biology 2019-08-13
-
Nanofocused Scanning X-ray Fluorescence Microscopy Revealing an Effect of Heterozygous Hemoglobin S and C on Biochemical Activities in
Analytical chemistry 2020-03-31
Christine Lansche
2 publications dans cette catégorie
Affiliations :
- 3Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.
Publications dans "Hémoglobine C" :
-
Hemoglobin S and C affect biomechanical membrane properties of
Communications biology 2019-08-13
-
Nanofocused Scanning X-ray Fluorescence Microscopy Revealing an Effect of Heterozygous Hemoglobin S and C on Biochemical Activities in
Analytical chemistry 2020-03-31
Michael Lanzer
2 publications dans cette catégorie
Affiliations :
- 3Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.
Publications dans "Hémoglobine C" :
-
Hemoglobin S and C affect biomechanical membrane properties of
Communications biology 2019-08-13
-
Nanofocused Scanning X-ray Fluorescence Microscopy Revealing an Effect of Heterozygous Hemoglobin S and C on Biochemical Activities in
Analytical chemistry 2020-03-31
Motomu Tanaka
2 publications dans cette catégorie
Affiliations :
- 1Physical Chemistry of Biosystems, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany.
- 7Center for Integrative Medicine and Physics, Institute for Advanced Study, Kyoto University, Kyoto, 606-8501 Japan.
Publications dans "Hémoglobine C" :
-
Hemoglobin S and C affect biomechanical membrane properties of
Communications biology 2019-08-13
-
Nanofocused Scanning X-ray Fluorescence Microscopy Revealing an Effect of Heterozygous Hemoglobin S and C on Biochemical Activities in
Analytical chemistry 2020-03-31
Lia-Raluca Olari
2 publications dans cette catégorie
Affiliations :
- Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Richard Bauer
2 publications dans cette catégorie
Affiliations :
- Institute of Medical Microbiology and Hygiene, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Rüdiger Groß
2 publications dans cette catégorie
Affiliations :
- Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Carina Conzelmann
2 publications dans cette catégorie
Affiliations :
- Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Fabian Gerbl
2 publications dans cette catégorie
Affiliations :
- Institute of Medical Microbiology and Hygiene, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Nico Preising
2 publications dans cette catégorie
Affiliations :
- Core Facility for Functional Peptidomics, Ulm Peptide Pharmaceuticals (U-PEP), Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Ludger Ständker
2 publications dans cette catégorie
Affiliations :
- Core Facility for Functional Peptidomics, Ulm Peptide Pharmaceuticals (U-PEP), Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Sebastian Wiese
2 publications dans cette catégorie
Affiliations :
- Core Unit of Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Elsa Sanchez-Garcia
2 publications dans cette catégorie
Affiliations :
- Computational Biochemistry, Center of Medical Biotechnology, University of Duisburg-Essen, 45141, Essen, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Tanja Weil
2 publications dans cette catégorie
Affiliations :
- Max-Planck-Institute for Polymer Research Mainz, 55128, Mainz, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Steffen Stenger
2 publications dans cette catégorie
Affiliations :
- Institute of Medical Microbiology and Hygiene, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Paul Walther
2 publications dans cette catégorie
Affiliations :
- Central Facility for Electron Microscopy, Ulm University, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Frank Kirchhoff
2 publications dans cette catégorie
Affiliations :
- Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Barbara Spellerberg
2 publications dans cette catégorie
Affiliations :
- Institute of Medical Microbiology and Hygiene, Ulm University Medical Center, 89081, Ulm, Germany.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Jan Münch
2 publications dans cette catégorie
Affiliations :
- Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany. jan.muench@uni-ulm.de.
- Core Unit of Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081, Ulm, Germany. jan.muench@uni-ulm.de.
Publications dans "Hémoglobine C" :
-
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties.
Cellular and molecular life sciences : CMLS 2023-05-17
-
A Placenta Derived C-Terminal Fragment of β-Hemoglobin With Combined Antibacterial and Antiviral Activity.
Frontiers in microbiology 2020-04-06
Sources (10000 au total)
Ocrelizumab for multiple sclerosis.
Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in ad... To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS.... We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies.... All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approv... We used standard methodological procedures expected by Cochrane.... Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo a... For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certai...
Alemtuzumab for multiple sclerosis.
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ... To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS.... We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022.... We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in... We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s... We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e... Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
[Multiple sclerosis treatments].
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according t...
Concurrent diagnoses of Tuberous sclerosis and multiple sclerosis.
Tuberous sclerosis (TS) is a monogenic disorder which causes disabling neurological symptoms. Similarly, multiple sclerosis (MS) may result in disability, but in contrast, is diagnosed without genetic...
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS).... MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues.... The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to ... A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional ana... The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices....
Ageing and multiple sclerosis.
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas ...
Immunosenescence and multiple sclerosis.
Changes in the immune system associated with ageing are known as immunosenescence. This is characterised by a decline in immune response, chronic inflammation and an increased risk of autoimmune disea...
[Treatment of multiple sclerosis].
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...
Pediatric Multiple Sclerosis.
The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized, as well as the evidence for performance of the most recent iteration of McDonald criteria in the pediatric...